CJC-1295 + Ipamorelin

Premium CJC-1295 (No DAC) + Ipamorelin — Dual-Pathway Growth Hormone Signaling System

Precision peptide combination designed for coordinated endocrine pathway research and controlled GH-axis signaling.

Why Choose Advatex Labs?

• Third-party tested for purity and consistency
• Strict batch tracking and quality control
• Research-grade lyophilized formulation
• Clean, lab-focused packaging
• Designed for advanced endocrine research applications

Description:

The combination of CJC-1295 (No DAC) and Ipamorelin represents a dual-pathway peptide system designed to study coordinated growth hormone signaling through two distinct yet complementary receptor mechanisms.

CJC-1295 (No DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), functioning by binding to GHRH receptors located in the anterior pituitary. This interaction stimulates downstream signaling pathways associated with growth hormone activity. The “No DAC” version is specifically characterized by its shorter duration of action, allowing for controlled and pulsatile receptor engagement that more closely mimics natural endocrine rhythms.

Ipamorelin, on the other hand, is a selective ghrelin receptor agonist that binds to the GHS-R1a receptor. This receptor is part of a separate signaling pathway involved in growth hormone regulation. Unlike earlier growth hormone secretagogues, Ipamorelin is known for its high receptor specificity, allowing targeted pathway activation without broad interaction across unrelated hormonal systems.

When combined, these two peptides create a synchronized signaling environment by activating both the GHRH receptor pathway and the ghrelin receptor pathway simultaneously. This dual activation allows researchers to study how these two systems interact, overlap, and coordinate within the endocrine network.

One of the key advantages of this combination is the ability to evaluate pulsatile signaling patterns. Because CJC-1295 (No DAC) has a shorter activity window, it allows for repeated, controlled receptor stimulation rather than continuous activation. When paired with Ipamorelin’s selective receptor engagement, this creates a model that more closely reflects natural biological signaling cycles.

This makes the CJC-1295 (No DAC) + Ipamorelin combination particularly valuable in research environments focused on hormone rhythm studies, pituitary signaling dynamics, and the interaction between multiple regulatory pathways within the endocrine system.

Additionally, the separation of receptor pathways reduces overlap and competition at the receptor level, enabling clearer observation of signaling effects and more precise analysis of biological responses.

Key Research Highlights:

• Dual-pathway peptide system (GHRH + GHS-R1a receptors)
• Combines CJC-1295 (No DAC) and Ipamorelin for coordinated signaling
• Supports pulsatile endocrine pathway research models
• High receptor specificity with minimal pathway overlap
• Enables study of pituitary signaling and GH-axis interaction
• Widely used in advanced endocrine and hormone regulation research

Quality & Transparency:

Each batch is produced under strict internal quality protocols to ensure consistency, stability, and traceability across all research applications. Every formulation is designed to meet high standards required for controlled laboratory research environments.

Important Notice:

This product is intended strictly for laboratory research purposes only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, or consumption.